Brussels, Belgium and Atlanta, GA – July 16, 2012 – UCB announced today that Neupro® (Rotigotine Transdermal System) is now available in U.S. pharmacies. Neupro® was approved by the U.S Food ...

UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a ...

ATLANTA, Dec. 13 /PRNewswire/ -- UCB announced today that the supplemental New Drug Application (sNDA) for the use of Neupro(R) as a treatment for moderate-to-severe restless legs syndrome (RLS) has ...

UCB has once again started selling its Neupro patch in the USA for Parkinson's disease and restless legs syndrome. UCB has once again started selling its Neupro patch in the USA for Parkinson’s ...

UCB has already made progress in reformulation and remains committed to bringing Neupro® to U.S. patients suffering from Parkinson's disease and Restless Leg Syndrome Brussels (Belgium ...

UCB now has three core brands: Cimzia, for Crohn's disease and rheumatoid arthritis (RA), epilepsy treatment Vimpat and Neupro for Parkinson's disease. These three products are sustaining the firm ...

After UCB tried once again to block generic competition to its Parkinson’s disease patch Neupro, an appeals court has handed a win to its generic rivals. In a decision this week, the U.S. Court ...

The company said in a statement on Tuesday that the Japanese Ministry of Health, Labour and Welfare had approved UCB’s Neupro patch to treat Parkinson’s disease and moderate-to-severe Restleg ...

The FINANCIAL — UCB announced on June 29 that Neupro (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available ...

So far, more than 100,000 patients have been treated with Neupro worldwide. UCB mentioned that presently around one million Americans are afflicted by PD and believes that up to 23 million ...